Billions of microbes. One gut. One remarkably complex ecosystem.

Your gastrointestinal tract is home to trillions of microorganisms that together form the gut microbiome. More than a digestive system, it is a dynamic ecosystem associated with digestion, intestinal barrier function, and immune activity. Diet, lifestyle, illness, and medications can all influence this microbial environment.

What Is the Gut Microbiome?

The gut microbiome is a diverse community of microorganisms that interact with one another and with the host. Modern research therefore looks beyond individual bacteria to understand microbial composition, interactions, and overall function.

Probiotics and Prebiotics: Two Approaches to Supporting the Gut Microbiome

• Probiotics are live microorganisms that, when administered in adequate amounts, provide a health benefit to the host. Their effects are strain- and formulation-specific, making the strain, combination, dose, intended application, and supporting clinical evidence important considerations.
• Prebiotics are substrates selectively utilized by host microorganisms that confer a health benefit. Rather than supplying microorganisms directly, prebiotics support the activity and growth of relevant resident microorganisms, providing a microbiome-directed approach to gut health.

Targeted Bacteriotherapy and the Future of Gut Health

Targeted bacterio-therapy is a next-generation treatment approach that uses specific, carefully selected bacteria to restore balance in the gut microbiome—rather than broadly wiping out both good and bad bacteria, as traditional antibiotics often do. By precisely identifying and addressing harmful bacterial imbalances, this therapy helps repair gut health at its root cause, paving the way for improved digestion, stronger immunity, and better overall wellness.

What Is Specialty Microbiome—And Why Does It Matter?

Specialty microbiome refers to probiotic formulations built around a defined, clinically studied strain combination tailored to a specific life stage or health condition—such as pregnancy, infancy, or chronic gut dysbiosis. It matters because gut health varies significantly across individuals: the microbial needs of a newborn, a pregnant woman, and someone managing dysbiosis are biologically distinct, and addressing them effectively requires a precise, condition-specific approach.

The De Simone Formulation™: Defined Strains, Defined Approach

The De Simone Formulation™ represents a defined eight-strain probiotic combination comprising selected Streptococcus, Bifidobacterium, and Lactobacillus strains. Its significance lies not simply in the number of strains, but in the specific combination, formulation, and clinical evidence associated with it.

Key Principle: Evidence for one defined probiotic formulation should not automatically be generalized to every probiotic product.

Next Gen Pharma’s Gut Health Approach

Next Gen Pharma focuses on gut-specific, formulation-driven microbiome solutions. Its portfolio includes

• CDS-22^™ (formerly Vivomixx®, part of the De Simone Formulation^™) is a high-potency, multi-strain probiotic containing 8 clinically studied bacterial strains. Backed by over 60 clinical trials, it supports gut microbiota balance and is used to manage dysbiosis, IBS, and IBD-related conditions. It’s available in multiple strengths—from 5 billion CFU drops for infants to 450 billion CFU sachets for adults—and is gluten-free and lactose-free.
• Evamixx® is a proprietary prenatal and postnatal probiotic blend formulated with the De Simone Formulation®, designed to support maternal gut health, breast-milk quality, and the long-term wellbeing of both mother and child. By nurturing a balanced gut microbiome during pregnancy and breastfeeding, Evamixx® aims to support digestive health, immune function, and a healthy start for the baby’s own developing microbiome.

This demonstrates how a defined microbial formulation can be adapted to different gastrointestinal and life-stage requirements.

Conclusion

As microbiome science continues to evolve, gut health is no longer just about probiotics—it’s about precision. Understanding which strains, at what dose and for what purpose defines real efficacy. Probiotics, prebiotics, and targeted bacterio-therapy each play a distinct yet complementary role, and together, they represent the future of personalized, evidence-based gut health.

At Next Gen Pharma, this scientific perspective guides the development of gut-focused solutions built around defined microbial formulations and evidence-informed approaches. Products incorporating the De Simone Formulation™ reflect the importance of a precisely defined strain combination rather than a generic, one-size-fits-all probiotic concept.

The future of gut health is not simply about more microorganisms—it is about the right microorganisms, the right formulation, and the right scientific evidence.